全球抗体药物复合体（ADC）市场规模、份额、趋势和成长分析报告：2026-2034年

抗体药物复合体(ADC) 市场预计将从 2025 年的 187.5 亿美元成长到 2034 年的 427.5 亿美元，2026 年至 2034 年的复合年增长率为 9.59%。

由于标靶癌症治疗的突破性进展，全球抗体药物复合体（ADC）市场正经历快速成长。 ADC将单株抗体与强效细胞毒性药物结合，能够将药物精准递送至癌细胞，同时最大限度地减少对健康组织的损伤。近年来，全球癌症发生率的上升和对个人化医疗需求的日益增长，显着推动了市场扩张。

成长要素包括对肿瘤学研究的大力投入、不断扩大的临床试验项目管线以及创新型抗体偶联药物（ADC）疗法的监管核准。製药公司正与生物技术公司合作，以改善连接子技术和有效载荷效率。生物标记辨识和伴随诊断技术的进步也增强了ADC的临床成功率，并加速了其在多种癌症适应症的应用。

抗体药物偶联物（ADC）市场前景仍十分光明，众多候选药物正处于后期研发阶段。抗体工程和药物偶联技术的创新可望进一步提升其疗效和安全性。随着医疗体係日益重视标靶治疗和精准肿瘤学，ADC有望在癌症治疗中发挥变革性作用，并推动市场持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球抗体药物复合体（ADC）市场：依应用领域划分

• 市场分析、洞察与预测
• 血癌
• 白血病
• 淋巴瘤
• 多发性骨髓瘤
• 乳癌
• 尿路上皮癌/膀胱癌
• 其他的

第五章 全球抗体药物复合体（ADC）市场：依产品划分

• 市场分析、洞察与预测
• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• 其他的

第六章 全球抗体药物复合体(ADC) 市场：以标靶划分

• 市场分析、洞察与预测
• HER2
• CD22
• CD30
• 其他的

第七章 全球抗体药物复合体（ADC）市场：依技术划分

• 市场分析、洞察与预测
• 类型
• 可切割连接器
• 不可分割的连接子
• 无连接器

第八章 全球抗体药物复合体(ADC) 市场：依连接子技术类型划分

• 市场分析、洞察与预测
• VC
• Sulfo-SPDB
• VA
• Hydrazone
• 其他的

第九章 全球抗体药物复合体（ADC）市场：依有效载荷技术划分

• 市场分析、洞察与预测
• MMAE
• MMAF
• DM4
• 喜树碱
• 其他的

第十章 全球抗体药物复合体（ADC）市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十一章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十二章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Seagen Inc
  • Takeda Pharmaceutical Company Ltd
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc
  • Gilead Sciences Inc
  • Daiichi Sankyo Company Ltd
  • GlaxoSmithKline Plc
  • Astellas Pharma Inc
  • ADC Therapeutics SA

The Antibody Drug Conjugates Market size is expected to reach USD 42.75 Billion in 2034 from USD 18.75 Billion (2025) growing at a CAGR of 9.59% during 2026-2034.

The Global Antibody Drug Conjugates (ADC) Market has experienced rapid growth due to breakthroughs in targeted cancer therapies. ADCs combine monoclonal antibodies with potent cytotoxic drugs, enabling precise delivery to cancer cells while minimizing damage to healthy tissue. Rising cancer prevalence worldwide and increasing demand for personalized medicine have significantly propelled market expansion over recent years.

Growth drivers include strong investment in oncology research, expanding clinical trial pipelines, and regulatory approvals for innovative ADC therapies. Pharmaceutical companies are collaborating with biotechnology firms to enhance linker technologies and payload efficiency. Advances in biomarker identification and companion diagnostics have also strengthened the clinical success of ADCs, driving their adoption in various cancer indications.

Future prospects for the ADC market remain highly promising, with numerous candidates in late-stage development. Technological innovations in antibody engineering and drug conjugation methods are expected to improve efficacy and safety profiles. As healthcare systems prioritize targeted therapies and precision oncology, ADCs are likely to play a transformative role in cancer treatment, supporting sustained market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

• Blood Cancer
• Leukemia
• Lymphoma
• Multiple Myeloma
• Breast Cancer
• Urothelial Cancer & Bladder Cancer
• Other Cancer

By Product

• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Others

By Target

• HER2
• CD22
• CD30
• Others

By Technology

• Type
• Cleavable Linker
• Non-cleavable Linker
• Linker less

By Linker Technology Type

• VC
• Sulfo-SPDB
• VA
• Hydrazone
• Others

By Payload Technology

• MMAE
• MMAF
• DM4
• Camptothecin
• Others

COMPANIES PROFILED

• Seagen Inc, Takeda Pharmaceutical Company Ltd, AstraZeneca, F HoffmannLa Roche Ltd, Pfizer Inc, Gilead Sciences Inc, Daiichi Sankyo Company Ltd, GlaxoSmithKline Plc, Astellas Pharma Inc, ADC Therapeutics SA

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Blood Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Multiple Myeloma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Urothelial Cancer & Bladder Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Other Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Kadcyla Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Enhertu Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Adcetris Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Padcev Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Trodelvy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Polivy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY TARGET 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Target
• 6.2. HER2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. CD22 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. CD30 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Technology
• 7.2. Type Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Cleavable Linker Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Non-cleavable Linker Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Linker less Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY LINKER TECHNOLOGY TYPE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Linker Technology Type
• 8.2. VC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Sulfo-SPDB Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. VA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Hydrazone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY PAYLOAD TECHNOLOGY 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Payload Technology
• 9.2. MMAE Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. MMAF Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. DM4 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Camptothecin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY REGION 2022-2034(USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Application
  • 10.2.2 By Product
  • 10.2.3 By Target
  • 10.2.4 By Technology
  • 10.2.5 By Linker Technology Type
  • 10.2.6 By Payload Technology
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Application
  • 10.3.2 By Product
  • 10.3.3 By Target
  • 10.3.4 By Technology
  • 10.3.5 By Linker Technology Type
  • 10.3.6 By Payload Technology
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Application
  • 10.4.2 By Product
  • 10.4.3 By Target
  • 10.4.4 By Technology
  • 10.4.5 By Linker Technology Type
  • 10.4.6 By Payload Technology
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Application
  • 10.5.2 By Product
  • 10.5.3 By Target
  • 10.5.4 By Technology
  • 10.5.5 By Linker Technology Type
  • 10.5.6 By Payload Technology
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 South East Asia
  • 10.5.12 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Application
  • 10.6.2 By Product
  • 10.6.3 By Target
  • 10.6.4 By Technology
  • 10.6.5 By Linker Technology Type
  • 10.6.6 By Payload Technology
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL ANTIBODY DRUG CONJUGATES INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Seagen Inc
  • 12.2.2 Takeda Pharmaceutical Company Ltd
  • 12.2.3 AstraZeneca
  • 12.2.4 F. Hoffmann-La Roche Ltd
  • 12.2.5 Pfizer Inc
  • 12.2.6 Gilead Sciences Inc
  • 12.2.7 Daiichi Sankyo Company Ltd
  • 12.2.8 GlaxoSmithKline Plc
  • 12.2.9 Astellas Pharma Inc
  • 12.2.10 ADC Therapeutics SA